Podcasts about gynecology

Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Substackhttps://substack.com/@theoccultrejects?r=7auau0&utm_campaign=profile&utm_medium=profile-pageCash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsGreek and Roman Primary SourcesAristotle. Generation of Animals. Translated by A. L. Peck. Loeb Classical Library 366. Cambridge, MA: Harvard University Press, 1942.Galen. On Semen. Edited and translated by Phillip De Lacy. Corpus Medicorum Graecorum V 3, 1–2. Berlin: Akademie-Verlag, 1992.Galen. On the Usefulness of the Parts of the Body. Translated by Margaret Tallmadge May. 2 vols. Ithaca, NY: Cornell University Press, 1968.Hippocrates. Generation, Nature of the Child, Diseases IV. Translated by Paul Potter. Loeb Classical Library 520. Cambridge, MA: Harvard University Press, 2012.Hippocrates. On the Seed and the Nature of the Child. In Hippocratic Writings, edited by G. E. R. Lloyd and translated by J. Chadwick and W. N. Mann. London: Penguin, 1978.Soranus. Soranus' Gynecology. Translated by Owsei Temkin. Baltimore: Johns Hopkins University Press, 1956.Greek and Roman Medicine, Gender, and SexualityConnell, Sophia M. Aristotle on Female Animals: A Study of the Generation of Animals. Cambridge: Cambridge University Press, 2016.Dean-Jones, Lesley. Women's Bodies in Classical Greek Science. Oxford: Clarendon Press, 1994.Flemming, Rebecca. Medicine and the Making of Roman Women: Gender, Nature, and Authority from Celsus to Galen. Oxford: Oxford University Press, 2000.King, Helen. Hippocrates' Woman: Reading the Female Body in Ancient Greece. London: Routledge, 1998.Laqueur, Thomas. Making Sex: Body and Gender from the Greeks to Freud. Cambridge, MA: Harvard University Press, 1990.Lloyd, G. E. R. Science, Folklore and Ideology: Studies in the Life Sciences in Ancient Greece. Cambridge: Cambridge University Press, 1983.Mattern, Susan P. The Prince of Medicine: Galen in the Roman Empire. Oxford: Oxford University Press, 2013.Nutton, Vivian. Ancient Medicine. 2nd ed. London: Routledge, 2013.Ayurveda, Kāma, and South Asian Sexual TraditionsDoniger, Wendy, and Sudhir Kakar, trans. Kamasutra. Oxford: Oxford University Press, 2002.Flood, Gavin. The Tantric Body: The Secret Tradition of Hindu Religion. London: I. B. Tauris, 2006.Meulenbeld, G. Jan. A History of Indian Medical Literature. 5 vols. Groningen: Egbert Forsten, 1999–2002.Sanderson, Alexis. “The Śaiva Age: The Rise and Dominance of Śaivism during the Early Medieval Period.” In Genesis and Development of Tantrism, edited by Shingo Einoo, 41–350. Tokyo: Institute of Oriental Culture, University of Tokyo, 2009.White, David Gordon. Kiss of the Yoginī: “Tantric Sex” in Its South Asian Contexts. Chicago: University of Chicago Press, 2003.White, David Gordon. The Alchemical Body: Siddha Traditions in Medieval India. Chicago: University of Chicago Press, 1996.Wujastyk, Dominik. The Roots of Ayurveda: Selections from Sanskrit Medical Writings. 3rd ed. London: Penguin, 2003.Chinese Medicine and Daoist CultivationDespeux, Catherine. Taoism and Self Knowledge: The Chart for the Cultivation of Perfection. Leiden: Brill, 2018.Furth, Charlotte. A Flourishing Yin: Gender in China's Medical History, 960–1665. Berkeley: University of California Press, 1999.Kohn, Livia. Daoist Body Cultivation: Traditional Models and Contemporary Practices. Magdalena, NM: Three Pines Press, 2006.Lo, Vivienne. “The Influence of Nurturing Life Culture on the Development of Western Han Acumoxa Therapy.” In Innovation in Chinese Medicine, edited by Elisabeth Hsu, 19–50. Cambridge: Cambridge University Press, 2001.Pregadio, Fabrizio, ed. The Encyclopedia of Taoism. 2 vols. London: Routledge, 2008.Schipper, Kristofer. The Taoist Body. Translated by Karen C. Duval. Berkeley: University of California Press, 1993.Wile, Douglas. Art of the Bedchamber: The Chinese Sexual Yoga Classics Including Women's Solo Meditation Texts. Albany: State University of New York Press, 1992.Comparative and Methodological StudiesFoucault, Michel. The History of Sexuality. Vol. 2, The Use of Pleasure. Translated by Robert Hurley. New York: Vintage Books, 1990.Hopwood, Nick, Rebecca Flemming, and Lauren Kassell, eds. Reproduction: Antiquity to the Present Day. Cambridge: Cambridge University Press, 2018.Wiesner-Hanks, Merry E., and Mathew Kuefler, eds. The Cambridge World History of Sexualities. Vol. 2, Systems of Thought and Belief. Cambridge: Cambridge University Press, 2024.Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. 

Picture this common, late-gestation conundrum: You're reviewing a 34-week sono. The mid-pregnancy 24-to-28-week glucose screen was completely normal. But now, the sonogram pops up with an estimated fetal weight of over 90%, or maybe a MVP (or AFI) that's overtly elevated. The classic clinical dilemma hits: Do you order a repeat OGTT this late in the game? Is it actually worth poking the patient again, or are you just chasing shadows? Well, we now have new meta-analytic data. Today, we are reviewing fresh, high-yield data hot off the press from the American Journal of Obstetrics & Gynecology (OCT 2026). We're breaking down this systematic review evaluating late-onset GDM- looking at precisely who may yield a positive diagnosis on a repeat third-trimester test, why LGA and polyhydramnios are not created equal when deciding to re-screen, and what these late numbers mean for neonatal hypoglycemia and cesarean delivery rates. AND, although these insights are helpful- some questions remain. Let's jump in!1. Dominsky O, Berkovitz-Shperling R, Rosenberg-Fridman M .Late-onset diagnosis of gestational diabetes after normal mid-pregnancy screening in women with large for gestational age or polyhydramnios: a systematic review and meta-analysis. American Journal of Obstetrics & Gynecology, 2026; 235, 789-799

Today we're diving into a lab order that almost every ob-gyn, midwife, and labor-and-delivery nurse were traditionally trained to do: the routine Postpartum Day 1 Hemoglobin and hematocrit. For decades, checking a patient's H&H after delivery was automatic. Didn't matter if it was a smooth, uncomplicated vaginal birth with minimal blood loss or a complex emergency C-section- come 6:00 AM the next morning, someone was drawing blood. Historically, the logic felt airtight: First, visual estimation of blood loss (the EBL) during delivery is notoriously inaccurate; clinicians often underestimate heavy bleeding by as much as 30 to 50 percent. Second, severe postpartum anemia can be sneaky. A patient might look fine lying in bed, but an undetected crash in hemoglobin can lead to severe fatigue, impaired bonding, delayed recovery, or even delayed postpartum hemorrhage complications. And third, early detection meant early intervention- giving iron or transfusing blood before the patient got discharged home. It was standard, it was defensive, and it felt safe. But here is the million-dollar question: Is a blanket, universal Postpartum H&H actually evidence-based in modern obstetric care? Or are we just poking healthy, asymptomatic patients, driving up healthcare costs, and treating lab numbers instead of the clinical patient? Today we will be looking at what the major guidelines, including ACOG, actually say, and why target-based screening has long replaced universal testing. Let's get into it!1. Ruiz de Viñaspre-Hernández R, Gea-Caballero V, Juárez-Vela R, Iruzubieta-Barragán FJ.The definition, screening, and treatment of postpartum anemia: A systematic review of guidelines. Birth. 2021. 2. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233.Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Obstetric3. Muñoz M, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med. 2018 Feb;28(1):22-39

MS is a complex polygenic disease with over 200 associated genetic variants. The risk of an offspring developing MS if one parent is affected is relatively low at 2% to 3% (though maternal transmission shows slightly higher heritability), with some possible epigenetic influences. The National Multiple Sclerosis Society reports that up to 4 times as many women have MS as men. The average age at MS diagnosis is around 30 years. Studies show this ratio has grown over the past several decades; in the mid-20th century, the ratio was roughly 2:1, but the proportion of affected females has steadily increased due to a combination of environmental, hormonal, and diagnostic factors. MS does not impair natural fertility, so OB providers should be aware of the effect of pregnancy on MS and vice verse. In this episode, we will review a brand new (as of Aug 8, 2026) expert review on the subject which was published in the AJOG. Over the last decade, clinical guidance has shifted from advising women with MS to avoid pregnancy to a more active and permissive stance, largely due to the advent of new pharmacological and biologic therapies. Listen in for details. 1. Balshi A, et al. Management of Multiple Sclerosis During Pregnancy and the Reproductive Years in 2026: An Expert Clinical Review, American Journal of Obstetrics and Gynecology (2026), doi: https://doi.org/10.1016/j.ajog.2026.08.043.

Dr. Maggie Runyon and The Birth Nurse, Mandy Irby, dove into research on obstetric violence culture to explore its multi-layered components and why it's so challenging to change. They discovered countercultural archetypes that disrupt the culture of obstetrics. Are you ready to be critically reflective of your clinical practice? Listen to this episode to understand where you're positioned and how you can expand to become an effective advocate for your patients and yourself. Meet our guests: Mandy Irby, BSN, RNC-OB, C-EFM, LCCE, NSI-L1  Read More Mandy Irby is a leading authority in transforming birth care culture through the prevention of birth-related trauma by co-creating The Embodied Trauma-Informed Care Framework. Since founding The Birth Nurse, she's worked with state quality collaboratives, departments of health, and hospital teams to strengthen psychological safety in childbirth and improve family outcomes across generations. Her paradigm-shifting workshops, keynote speeches, and consultations drive the change to patient-centered care within a safe and ethical framework for nurses. Maggie Runyon, MSN, RNC-OB, CYT-200  Read More Maggie Runyon is a nurse, educator, writer, and speaker. She began her nursing career in 2009 and has since practiced in hospitals and communities around the country. In 2019, Maggie founded the non-profit Your BIRTH Partners with a mission to cultivate inclusive, collaborative birth care environments rooted in autonomy, respect, and equity. Maggie recently earned her PhD in Nursing and loves educating, mentoring, and learning alongside nurses. In 2025, she authored her first book, I Thought I Was Here to Help, which chronicles her early career journey and the lessons she has learned. Her advocacy focuses on improving perinatal care in hospital environments through trauma-informed care, affirming nurses' agency, and community collaboration. Episode Resources American College of Obstetricians and Gynecologists. (2025). Pain management for in-office uterine and cervical procedures. Clinical Consensus No. 9. Obstetrics & Gynecology, 146, 161-177. Morse, B. (2026). Pain care during intrauterine device insertion: Nurses taking the lead. Nursing for Women's Health, 30(3), 234-247. doi: 10.1016/j.nwh.2025.12.004. 2026 NWH Excellence in Writing Award Winning Paper Morse, B. (2025). Sleepy but supported: Helping caregivers navigate newborn sleep. Nursing for Women's Health, 29(6), 383-392. doi: 10.1016/j.nwh.2025.07.005. Dan Siegel's Resources [Coined the Window of Tolerance Concept] Mind My Peelings Runyon, M. C., Irby, M. N., Landivar, P. Rojas, Pascucci, C. (2026). Reframing obstetric violence culture: A concept analysis. Journal of Advanced Nursing, 82(6), 5892-5922. https://doi.org/10.1111/jan.70323. What's Your Resistance Avatar? Meet 3 Nurses Already Disrupting Obstetric Violence Culture The post Disrupting Obstetric Violence appeared first on AWHONN.

Join us for a FREE live Q&A with Dr. Salcedo on September 10 at 9:00 AM PT / 12:00 PM ET and ask her your questions directly. Register here.What if the uterus is an end organ, responding to insulin and inflammation the same way the heart, kidneys, and liver do?Dr. Andréa Salcedo is a board-certified OBGYN (DO, MPH, FACOG) and associate professor at Loma Linda University School of Medicine whose research and clinical practice, which she calls conscious gynecology, examine gynecologic disease through a metabolic lens.In this episode she walks through the evidence that uterine fibroids share progenitor cells with atherosclerotic plaque, why she now teaches residents that fibroids are cardiovascular disease of the uterus, and how high insulin acts at the level of the brain stem to block ovulation. The conversation also covers her clinical observations on fasting insulin thresholds by body type, the renaming of PCOS to PMOS, what hormonal contraceptives do and do not treat, the role of chronic stress and adversity in gynecologic disease, and the four insulin-resistant transitions of a woman's life.Questions Answered in This Episode:Why are uterine fibroids being reframed as cardiovascular disease of the uterus?Can the menstrual cycle function as a metabolic vital sign?How does insulin, acting as a stress hormone, shut down ovulation?Is there an optimal fasting insulin for reproductive health, and does body type change the answer?What does the shift from PCOS to PMOS change for diagnosis and treatment?What happens to insulin resistance in perimenopause, and was the Women's Health Initiative misread?Viewers will come away with a physiological framework that treats heavy periods, fibroids, irregular cycles, and PCOS as early signals of metabolic dysfunction rather than isolated hormone problems.Special thanks to the sponsors of this episode:✅ Genova Connect: Get 15% off any Genova Connect test kit with code METABOLICLINK here. ✅ Cowboy Colostrum: Get 25% off your entire order with code METABOLIC here. ✅ Zocdoc: Find and instantly book a top-rated doctor here. ✅ fatty15: Get 15% off a 90-day starter kit with code METABOLICLINK here.More LinksLive Q&A with Dr. Salcedo, September 10, 9:00 AM PT (free): register hereDr. Salcedo's website: consciousgynecology.comDr. Salcedo on YouTube: @consciousgynecologistDr. Salcedo on Instagram: @consciousgynecologistPaper: The uterus is an end organ: a preliminary study of the association between abnormal uterine bleeding and hyperinsulinemia (Menopause, 2025)Paper: Therapeutic Carbohydrate Restriction as a Metabolic Modality for the Prevention and Treatment of Abnormal Uterine Bleeding (Nutrients, 2023)Dr. Salcedo is speaking on chronic stress, adversity, and gynecologic health at the Ketogenic Foundation conferenceThe Metabolic Initiative (expert lectures, CME, ad-free episodes, live Q&As; first 7 days free): membership.metabolicinitiative.comIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: InstagramFacebookYouTubeLinkedInPlease keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

So, here is a not uncommon situation: A new OB patient presents for initial prenatal care at 28 weeks by “sure LMP” but her ultrasound EGA is just over 3 weeks behind. Simple redating, right? How can we be assured that we are not missing FGR? That is where the “ancillary” use of transcerebellar diameter (TCD) plays a role. In this episode, we will highlight the recent JUNE 2026 data on this and review the 4 scenarios when this supplemental ultrasound finding can play a vital role. 1. Fetal Transcerebellar Diameter Measurement With Particular Emphasis in the Third Trimester: A Reliable Predictor of Gestational Age. AJOG. 2004. 2. Elgadi A, Wagealla M, Idris E, Eissa AYH, Altraifi S, Altraifi H, Abdallah E, Noorallah T, AbdAlla E. Accuracy of Ultrasonographic Transcerebellar Diameter for Gestational Age Estimation: A Systematic Review and Meta-Analysis. J Clin Ultrasound. 2026 Jun 17.3. ACOG Committee on Obstetric Practice. Committee Opinion No 700: Methods for Estimating the Due Date.Obstetrics and Gynecology. 2017. 4. Arzik IG, Golbasi H, Can ST, Aktas HA, Cakir ZE, Purut CS, Torun R, Toka I, Oztataroglu C, Ekin A. Role of Transcerebellar Diameter in Estimating Gestational Age in the Third Trimester: A Comparative Analysis in Fetuses With Different Growth Patterns. J Ultrasound Med. 2026 Apr;45(4):895-903.

Today we are diving into a topic that is incredibly close to my heart—one that has the potential to fundamentally change how we approach prenatal care and protect pregnant patients. We're talking about low-dose aspirin for the prevention of hypertensive disorders of pregnancy. Now, if you follow current formal guidelines, you probably know the standard protocol: 81 milligrams a day, prescribed based on specific risk factors. But there's a growing body of evidence suggesting we might be underdosing—and under-prescribing. What if 162 milligrams taken universally across the board is actually far more effective?In today's episode, we're unpacking a brand-new, groundbreaking study published in the American Journal of Obstetrics & Gynecology. And I'm especially excited to cover this one because it comes straight out of my alma mater, Parkland Hospital! This study takes a bold look at real-world outcomes by comparing a period of universal 162-milligram aspirin use directly against a historical period when aspirin wasn't recommended at all. Did a higher, universal dose significantly cut down on hypertensive disorders? And just as importantly …were there any adverse safety events we need to be aware of? Grab your coffee, settle in, and let's get into the details.1. Duryea E, Ambia A, Pruszynski J. et al. Universal Aspirin Dispensation for Prevention of Preeclampsia in a High-Risk Population. AJOG, 2026; ePub 8/27/282. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. 3. ACOG Issues Updated Hypertension Guidance, Discusses New ACC/AHA Criteria (2018): https://www.acog.org/news/news-releases/2018/12/acog-issues-updated-hypertension-guidance4. Low-Dose Aspirin Use During Pregnancy, ACOG Committee Opinion Number 743 (2018)5. Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. ACOG Practice Advisory; December 2021

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Elizabeth Tobin-Tyler is a professor of health services, policy and practice at the Brown University School of Public Health and of family medicine and medical science at Warren Alpert Medical School of Brown University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E. Tobin-Tyler and G. Chalker. Telehealth Access to Mifepristone — Evaluating Reproductive-Coercion Arguments. N Engl J Med 2026;395:833-835.

Gretchen Sisson, PhD, is a sociologist who studies abortion and adoption in the United States. She is a researcher at Advancing New Standards in Reproductive Health, part of the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco. Her research examining adoption decision-making after abortion denial (as part of The Turnaway Study) was cited in the Supreme Court's dissent in Dobbs v. Jackson Women's Health from Justices Breyer, Kagan, and Sotomayor. In response to the oral arguments and decision in Dobbs, she authored pieces in the Washington Post, The Nation, and the Washington Post (again). Gretchen's research been featured on NPR's All Things Considered and Consider This, as well as in New York Magazine, VOX, and other outlets.https://www.gretchensisson.comMusic by Corey Quinn

Today, we are tackling a massive grey area in obstetrics/maternal-fetal medicine: What happens after early fetal growth restriction resolves? When a baby bounces back on the growth chart during the second or third trimester, are they completely out of the woods? Or is there a hidden, lingering risk we aren't talking about enough? To find out, we're doing a deep dive into two major publications that dropped just this month, in August 2026 in sister journals (AJOG and AJOG MFM). Both are retrospective, both ask the exact same burning question…and get this: they arrive at completely opposing conclusions. How is that possible? Listen in for details. 1. Melamed B, Mei-Dan E, Aviram A. Sonographic fetal weight estimation percentiles should be interpreted with caution in the second trimester. Int J Gynaecol Obstet. 2026 May;173(2):930-939. doi: 10.1002/ijgo.70693. Epub 2025 Nov 25. PMID: 41288086.2. Ramos SZ, Has P, Gimovsky AC, Danilack VA, Savitz DA, Lewkowitz AK. Outcomes among Neonates after a Diagnosis of Persistent or Transient Fetal Growth Restriction Delivered at Term. Am J Perinatol. 2024 May;41(S 01):e1470-e1477. doi: 10.1055/a-2051-3859. Epub 2023 Mar 9. Erratum in: Am J Perinatol. 2024 May;41(S 01):e1478. doi: 10.1055/s-0044-1786526. PMID: 36894159; PMCID: PMC10562520.3. Keller N, Jackson F, Abelman S .Neonatal morbidity following resolution of fetal growth restriction diagnosed at second-trimester anatomy ultrasound. American Journal of Obstetrics & Gynecology MFM, 2026; Aug 8. 4. Cenac LA, Wodoslawsky S, Patel V, McLaren Jr. R, Aghai ZH, Makhamreh MM, Al-Kouatly HB, Persistent, Resolved, and Absent Fetal Growth Restriction: A Comparison of Neonatal Outcomes, American Journal of Obstetrics and Gynecology (2026), doi: https:// doi.org/10.1016/j.ajog.2026. Aug 19

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Endometrial cancer cases are rising — and abnormal bleeding is the warning sign women should never ignore. Who is most at risk, why are more women being diagnosed, and what symptoms should prompt a call to your doctor?In this episode of Baptist Health Talk, host Sandra Peebles speaks with Dr. John Diaz, gynecological oncologist at the Herbert Wertheim Cancer Institute, about what women need to know about endometrial cancer, from early warning signs and risk factors to diagnosis, treatment and fertility-preserving options. Why endometrial cancer cases are increasing in the U.S. and around the world  How obesity and prolonged estrogen exposure can raise risk  The abnormal bleeding patterns women should report — including after menopause  Other warning signs such as pelvic pain, bloating and abnormal discharge  Why endometrial cancer can also affect younger women  How doctors diagnose endometrial cancer and why there is no routine screening test  Treatment options for early and advanced disease, including immunotherapy  When fertility-sparing treatment may be possible  How family history and Lynch syndrome can affect riskHost:Sandra PeeblesAward-Winning JournalistGuest:John P. Diaz, M.D.Chief of Gynecologic OncologyHerbert Wertheim Cancer InstituteChair, Obstetrics & Gynecology, FIUIf you found this episode helpful, we also recommend the following:Can Cervical Cancer Be Cured? A Gynecologic Oncologist AnswersEradicating Cervical Cancer: Possible or Impractical?

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Dr. Braverman is a Clinical Professor with a joint appointment in the Department of Obstetrics and Gynecology and Psychiatry and Behavioral Medicine at Thomas Jefferson University. Dr. Braverman is the Associate Director for the Educational Core for OB/Gyn. She is a health psychologist with a specialty in medical health management, infertility counseling, and third party reproduction issues. She received her M.A., M.S. and Ph.D. in psychology from the University of Pennsylvania. Dr. Braverman has lectured internationally on treatment issues and reproductive medicine before medical and patient audiences. Dr. Braverman has published in medical journals about the psychological aspects of infertility, issues involved in the decision to end treatment, and psychological issues involved in using third-party donors. Dr. Braverman received the Timothy Jeffries Memorial award in 2011 for outstanding contributions as a health psychologist from the American Psychological Association and the 2021 Suheil J. Muasher, M.D., Distinguished Service Award from the American Society for Reproductive Medicine. CONNECT WITH DVORA ENTIN: Website: https://www.dvoraentin.com/ Instagram: https://www.instagram.com/dvoraentin YouTube: https://www.youtube.com/@misconceptionspodcast  

Recent research shows that between 40 and 60% of women either change or quit their sport due to bladder leaks. That's 100% too many in our book. So this week we sat down with Dr. Lauren Siff, a double board-certified urogynecologist to demystify one of women's health's most under-discussed issues: urinary leakage. We break down the differences between stress and urge incontinence, why athletes and active women are prone to leaking, and how the menopausal transition can worsen the situation through declining estrogen, shifting vaginal pH, and rising UTI risk. Dr. Siff walks us through the full range of solutions, from pelvic floor exercises and support devices to Botox, bladder stimulators, and the game-changing role of vaginal estrogen, plus how to know when it's time to seek care. Her message is loud and clear in this one: no matter how small or severe the symptoms, there's help available — and you never have to stop doing what you love.Dr. Siff is a double board-certified urogynecologist and Chief of Gynecology and Urogynecology for the Central Virginia VA Health Care System and Associate Professor at VCU School of Medicine and VCU Institute of Engineering. A dedicated innovator and surgical educator — with a Distinguished Educator certificate from the Cleveland Clinic and founder of SurgicalEd VR, which uses VR and haptic technology to improve the quality, safety, cost-effectiveness, and accessibility of surgical training. She also serves board and committee roles with the Society for Gynecologic Surgeons, American Urogynecologic Society, and American Association of GYN Laparoscopists. She is Central Virginia Site Lead for the National VA Women's Health Research Network, and chairman of the U.S. National Surgery Office's Surgical Advisory Board for GYN. Philanthropically, she directs surgeon training for Global Surgical Expedition, driven by a mission to democratize access to surgical training and vital surgical procedures worldwide.FeistyFit Info: https://livefeisty.com/training/running/feistyfitfall/Join us at Feisty Fest September 18-20, 2026: https://livefeisty.com/events/feisty-fest/Women's Mechanic Camp in Tucson: https://livefeisty.com/events/bike-mechanic-school-tucson/Courses and Coaching: https://livefeisty.com/courses/Sign up for our FREE Feisty 40+ newsletter: https://livefeisty.com/newsletters/feisty-40/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 15% off your order with code HITPLAY at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr

Today, we are taking a deep dive into a medical truth thatsounds completely counterintuitive, almost upside down, based on everything you think you know about women's health. But here's the kicker: it's actually nothing new at all. For over two decades, ever since the landmark Women'sHealth Initiative (WHI) study made global headlines back in 2002, the blanket narrative surrounding menopausal hormone therapy has been clear and persistent: hormones equal breast cancer risk. But there is a massive asterisk in thatscience that got completely lost in the media noise. While combination therapy with conjugated equine estrogens paired with medroxyprogesterone acetate (CEE +MPA) did show an increased risk, the story for estrogen-only therapy (mainly CEE) in women wh had a hysterectomy is entirely different. In fact, an overwhelming mountain of growing data shows that estrogen-only therapy is protectiveagainst both breast cancer incidence and breast cancer mortality. In this episode, we're unpacking the latest high-level evidence that cements this crucial distinction. We'll examine the broad statistical landscape, including a comprehensive meta-analysis by Qing et al. (officially set for the December 2026 issue of Annals of Medicine, following its ahead-of-print release in March 2026). Their work breaks down how randomized controlled trial data consistentlypoint to estrogen-only therapy having a protective effect, in stark contrast to combination therapy. We'll also dive into a brand-new Clinical Perspective published in mid-August 2026 in Obstetrics & Gynecology (the Green Journal) by Drs. Andrew Kaunitz and Jason Wright. They call urgent attention to this phenomenon, highlighting RCT meta-analyses that demonstrate a 23% reduction in breast cancer incidence with estrogen alone (RR = 0.77), alongside striking cohort data showing a dramatic risk reduction even in high-risk populations, like carriers of the BRCA mutation.  Listenin for details.1.     Wu Q, Shen L, Hu S, Yang R, Wang Y, Xue D, SunY, Ma H, Dai Z. Relationship between menopausal hormone therapy and incidencerisk of breast cancer: systematic review and meta-analysis. Ann Med. 2026Dec;58(1):2640244. doi: 10.1080/07853890.2026.2640244. Epub 2026 Mar.2.     Kaunitz, Wright. Menopausal Estrogen Therapy andRisk of Breast Cancer. Obstet Gynecol. Aug 20263.     Chlebowski RT, Aragaki AK, Pan K, et al.Randomized Trials of Estrogen-Alone and Breast Cancer Incidence: AMeta-Analysis. Breast Cancer Research and Treatment. 2024. 4.     Writing Group for the Women's Health InitiativeInvestigators. (2002). Risks and benefits of estrogen plus progestin in healthypostmenopausal women: Principal results from the Women's Health Initiativerandomized controlled trial. JAMA, 288(3), 321–333.

Infant mortality in Northeast Ohio continues at higher level than national averageInfant mortality refers to the death of an infant before they reach their first birthday. In Northeast Ohio, physicians and families have witnessed a constant rate of infant mortality over double the national average. There are many barriers that contribute to this issue including access to care, education and economic stressors. In 2024, the infant mortality rate for Black babies in Summit County was 19.4 deaths per 1,000 live births. This was over triple the rate for the total population nationally that same year. This number has risen over a decade since it first peaked in 2011. Why are babies in Ohio at a higher risk than other parts of the country? And what efforts are physicians and community organizations taking to reduce these numbers? On Wednesday, Aug. 19, Case Western Reserve University's Communication Sciences program and United Cerebral Palsy of Greater Cleveland are offering free development screenings for children ages 0 to 3. No appointment is required; however, they recommend reserving a time slot before arrival. Project Ujima's Queens Village will host "Honoring Black Birth, Protecting Black Babies", a community gathering centered around infant mortality, on Aug. 27 from 4:30-8 p.m. at United Way of Summit and Medina. Registration is free. Applications for Rx Kids will open to Ohioans on Sept. 1. The program, which initially saw success in Flint, Michigan, will be available for Cleveland parents who live in zip codes 44103, 44110 and 44114. Rx Kids provides expectant mothers with $1,500 cash payments during pregnancy and $500 per month for the first six months of their baby's life. Guests:- Jessica Wilder, M.D., Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, MetroHealth- LaKesh Duke, Executive Director, Project Ujima- Krista Lumpkins-Howard, Director of Training and Community Outreach, Birthing Beautiful Communities "Impossible Choices" and Maternal HealthIn June 2022, the U.S. Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization, overturned Roe versus Wade, which ended nearly 50 years of federal abortion access. This returned authority to individual states. Doctors and patients confronting high-risk pregnancies have always faced profound and life-altering decisions, but in the aftermath of the Dobbs decision, those decisions took on new weight and complications. David Hackney, a Northeast Ohio physician who specializes in maternal fetal medicine has written about this topic in a new book, "Impossible Choices: A Physician's Guidance on High-Risk Pregnancy in a World Without Roe." Hackney recently spoke with Ideastream's Morning Edition Host Amy Eddings about the book and his experience as a practicing OB/GYN post-Roe. You can find more of Amy Eddings reporting about reproductive rights in Ohio in her "Ohio After Roe" documentary here. Guests:- David Hackney, M.D., Maternal and Fetal Medicine, OB/GYN and Women's Health; Reproductive Biology, Case Western Reserve University- Amy Eddings, Host, Morning Edition, Ideastream Public Media

Today, we are taking a deep dive into an intervention that almost every labor and delivery unit in North America has adopted over the last decade: Quantitative Blood Loss, or QBL. ACOG first recommended quantitative blood loss assessment in Committee Opinion Number 794, published in December 2019. This opinion recommended that every birthing facility implement a standardized, quantitative method for measuring cumulative blood loss at all deliveries, replacing visual estimation as the default approach. This built on earlier ACOG efforts, including the 2015 reVITALize initiative, which standardized obstetric data definitions and defined postpartum hemorrhage using cumulative measured blood loss thresholds (≥1,000 mL regardless of delivery route, or blood loss accompanied by signs/symptoms of hypovolemia). We've all weighed sponges, measured calibrated drapes, and run the math. But here's the million-dollar question: Does measuring blood loss accurately, on its own, actually improve outcomes for patients? The answer is YES….and NO at the same time. Listen in for details as we discuss new data (July 2026 in AJOG) on this topic. 1. White A, Burns RN, Pruszynski JE, Ravindra D, Fin KX, Montgomery T, Jestes E, Ambia AM, Anyaehie B, Duryea EL. Establishing Normal Blood Loss Thresholds at the Time of Delivery Based on Quantitative Blood Loss. Am J Obstet Gynecol. 2026 Jul. DOI: 10.1016/j.ajog.2026.07.028. S0002-9378(26)00395-9. YMOB 16849.2. Quantitative Blood Loss in Obstetric Hemorrhage: ACOG COMMITTEE OPINION, Number 794.Obstetrics and Gynecology. 2019. Committee on Obstetric Practice3. Coomarasamy A, Devall AJ, Bell S, et al. Diagnosis and Treatment of Postpartum Haemorrhage: A Race Against Time. Lancet. 2026.

One of the deadliest forms of cancer for women may not start where we once believed. Researchers now know nearly all fatal ovarian cancers begin in the fallopian tubes, not the ovaries. Stephanie Sy discusses with Dr. Rebecca Stone, a professor in the Johns Hopkins Department of Gynecology and Obstetrics, how this understanding is important for patient care. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Fibroids are common but treatment isn't one-size-fits-all. In this podcast, Natalie Friedricks, MD, Medical Director of the Salinas Valley Health Obstetrics and Gynecology clinic, discusses when fibroids need treatment and the benefits of minimally invasive robotic surgery.#Fibroids #WomensHealth #RoboticSurgery #MinimallyInvasiveSurgery #OBGYN #AskTheExperts #SalinasValleyHealth  Learn more about Natalie Friedricks, MD 

Today, I want to tell you a story that sounds like it was completely made up for a movie script, but it's 100% real. Imagine an automotive mechanic in Argentina. He has zero medical training, no background in obstetrics, and no clinical degree. One night, he sees a simple party trick on YouTube: how to get a lost cork out of the inside of an empty wine bottle using nothing more than an inflated plastic bag. Most people would laugh, finish their glass of wine, and move on. But this mechanic, Jorge Odón, looked at that plastic bag and had a radical thought: Could this same basic physics principle be used to safely deliver a trapped baby during second-stage labor? Fast forward through years of engineering refinements, global partnerships, and early clinical pilots, and we get the Odón device- or OdonAssist™. It is, without a doubt, one of the most creative and innovative mechanical concepts to hit the field of operative vaginal delivery in generations. Instead of rigid metal blades applying direct compression, or high-pressure suction cups on the scalp, it uses an inflatable pneumatic cuff wrapped inside a lubricated, double-layered polyethylene sleeve. The inner layer grips the fetal vertex, while the outer layer glides smoothly against the vaginal walls, replacing high friction with plastic-on-plastic sliding action. But, and this is a big "but", as clinicians, we don't practice medicine based on good ideas or clever engineering alone. We practice based on rigorous, reproducible evidence on efficacy and safety. And that's where the narrative gets complicated. Although the device recently secured CE mark approval in Europe, it is not FDA approved in the United States. Why? Because despite nearly two decades of development, it is still facing a major shortage of large-scale Phase 3 comparative data (non-inferiority data). And the data it does have is not quite as impressive as its design would imply. Listen in for details. 1. Mottet N, et al. Safety and efficacy of the OdonAssist inflatable device for assisted vaginal birth: the BESANCON ASSIST study. American Journal of Obstetrics & Gynecology, 2023; 230, S947-S9582. Hotton EJ, Lenguerrand E, Wade J, et al. The OdonAssist inflatable device for assisted vaginal birth—the ASSIST II study (United Kingdom). Am J Obstet Gynecol. 2024;230(3S):S932-S946.e3.3. https://www.mnhi.com/odonassist (CE approval)4. ACOG PB 219; 2020.

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateEditorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USAFeaturing: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaRichard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USAOlle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, SwedenCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

In part 2 of this episode of The Phoenix Cast, Violence Prevention Educator Cassandra Carmona-Wayman (she/hers/ella) continues her conversation with reproductive health advocate Cristina Ponce (she/hers) about Abortion Access, Reproductive Coercion, and Survivor Autonomy. Cristina shares her abortion story and shares her lived experiences with these topics. We also unpack how shifting laws, financial barriers, and crisis pregnancy centers impact survivor autonomy and safety. We highlight practical resources like abortion funds, doulas, travel support, and trusted clinic locators. We also break down myths about medication abortion and centering abortion as both healthcare and a crucial safety option for survivors of violence.Content warnings: discussion of abortion (including personal and self-managed abortion stories), reproductive coercion, intimate partner and interpersonal violence, sexual violence (including rape and sexual coercion), pregnancy-related homicide risk, and anti-abortion harassment/misinformation.Additionally:We discuss healthcare clinics and abortion providers near the Denver Metro area. Please be aware of clinics that misrepresent their services and can appear misleading to patients in need of care. Some “crisis pregnancy centers” near campus and in Denver are not medical clinics and may offer misleading or incomplete information about abortion and pregnancy options. When you can, seek licensed providers or clinics that clearly offer full-spectrum reproductive healthcare, and remember you can reach out to the Phoenix Center at Auraria for confidential support and accurate referrals.Sources and Resources mentioned in the episode:American College of Obstetricians and Gynecologists. Committee Opinion No. 554: Reproductive and Sexual Coercion. American College of Obstetricians and Gynecologists, 2013.American College of Obstetricians and Gynecologists. “Reproductive and Sexual Coercion.” ACOG, Feb. 2013,  https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/02/reproductive-and-sexual-coercion.Centers for Disease Control and Prevention. “About Violence and Pregnancy.” Centers for Disease Control and Prevention,  https://www.cdc.gov/intimate-partner-violence/about/violence-and-pregnancy.html.Centers for Disease Control and Prevention. “Pregnancy Resulting from Sexual Violence.” Centers for Disease Control and Prevention,  https://www.cdc.gov/sexual-violence/about/pregnancy-resulting-from-sexualviolence.html.Cobalt Abortion Fund. Cobalt Abortion Fund,  https://cobaltaf.org/.Colorado Doula Project. Colorado Doula Project,  https://www.coloradodoulaproject.org/.Foster, Diana Greene. The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion. Scribner, 2020.Grace, Kelsey T., and Julie C. Anderson. “Reproductive Coercion: A Systematic Review.” Journal of Midwifery & Women's Health, vol. 63, no. 4, 2018, pp. 371–84.Guttmacher Institute. U.S. Abortion Patient and Policy Reports. Guttmacher Institute, https://www.guttmacher.org.Miller, Elizabeth, et al. “Pregnancy Coercion, Intimate Partner Violence and Unintended Pregnancy.” Contraception, vol. 81, no. 4, 2010, pp. 316–22.National Abortion Federation. National Abortion Federation,  https://prochoice.org/.National Academies of Sciences, Engineering, and Medicine. The Safety and Quality of Abortion Care in the United States. National Academies Press, 2018.“North Carolina Bill Would Authorize Deadly Force for Women Seeking Abortions.” WCNC Charlotte,  https://www.wcnc.com/article/news/politics/north-carolina-politics/north-carolina-bill-would-authorize-deadly-force-for-women-seeking-abortions/275-353d54a3-9231-4341-ae44-a127546db76f.Raymond, Elizabeth G., and David A. Grimes. “The Comparative Safety of Legal Induced Abortion and Childbirth in the United States.” Obstetrics & Gynecology, vol. 119, no. 2, 2012, pp. 215–19.“Reproductive Coercion.” The National Domestic Violence Hotline,  https://www.thehotline.org/resources/reproductive-coercion/.“Reproductive Coercion: What Is It?” Teen Vogue,  https://www.teenvogue.com/story/what-is-reproductive-coercion.Sexual Assault Awareness Fund. “Bisexual Women Are More Likely to Have Abortions.” Sexual Assault Awareness Fund, https://saafund.org/bisexual-women-are-more-likely-to-have-abortions/.Society of Family Planning. #WeCount Reports on Abortion Access After Dobbs.Society of Family Planning,  https://societyfp.org/.Tarzia, Laura, et al. “Reproductive Coercion and Abuse: A Systematic Review of Qualitative Evidence.” Trauma, Violence, & Abuse,  https://pmc.ncbi.nlm.nih.gov/articles/PMC5819992/.Van Parys, An-Sofie, et al. “Prevalence and Evolution of Intimate Partner Violence before and during Pregnancy: A Cross-Sectional Study.” BMC Pregnancy and Childbirth, vol. 14, 2014, article 294,  https://doi.org/10.1186/1471-2393-14-294.Washington State Coalition Against Domestic Violence. Pregnancy and Domestic Violence Issue Brief. Washington State Coalition Against Domestic Violence, 2013,  https://wscadv.org/wp-content/uploads/2016/12/pregnancy-dvfr-issue-brief-12-2013.pdf.World Health Organization. Abortion Care Guideline. World Health Organization, 2022.You can learn more about your options with healthcare service providers like Just the Pill. They can provide vital information and assistance with abortion, contraception, and other sexual and reproductive health services. We provide efficient and equitable access to health care by telemedicine. https://justthepill.com/about-us/You can also look into resources like Elevated Access. They are a nonprofit organization that provides free air transportation through a network of volunteer pilots, helping people travel to essential healthcare services they might not otherwise be able to reach. Their services primarily support access to abortion care and gender-affirming care by coordinating safe, confidential flights in partnership with healthcare and advocacy organizations across the United States.Be aware of Denver Metro Crisis Pregnancy Centers (CPCs):The AVI Project https://www.theaviproject.com/Alternatives Pregnancy Center (Alternatives Colorado) https://youhavealternatives.org/Bella Health and Wellness. Bella Health and Wellness.  https://bellahealthandwellness.com/.Alternatives Pregnancy Center. Alternatives Pregnancy Center.  https://youhavealternatives.org/.Marisol Health. Marisol Health.  https://marisolhealth.com/.Life Choices. Life Choices.  https://lifechoices.org/.If you are in crisis and need immediate support, please call our 24/7 interpersonal violence helpline at 303-556-2255.Request an Appointment with an Advocate athttps://www.thepca.org/online-appointment-requestRequest a Violence Prevention Presentation at https://www.thepca.org/prevention-educationInstagram @phoenixauraria

In part 1 of this episode of The Phoenix Cast, Violence Prevention Educator Cassandra Carmona-Wayman (she/hers/ella) talks with reproductive health advocate Cristina Ponce (she/hers) about how abortion care works, common myths about abortion, and the impact of post‑Dobbs restrictions. They also explore reproductive coercion as a form of abuse, its connections to interpersonal violence, and why protecting survivors' bodily autonomy and access to abortion is essential.Content warnings: discussion of intimate partner violence, reproductive coercion, sexual and physical violence, abortion (including later‑term), pregnancy loss, legal and systemic barriers to care, and brief mention of hospitalization due to assault.Additionally:We discuss healthcare clinics and abortion providers near the Denver Metro area. Please be aware of clinics that misrepresent their services and can appear misleading to patients in need of care. Some “crisis pregnancy centers” near campus and in Denver are not medical clinics and may offer misleading or incomplete information about abortion and pregnancy options. When you can, seek licensed providers or clinics that clearly offer full-spectrum reproductive healthcare, and remember you can reach out to the Phoenix Center at Auraria for confidential support and accurate referrals.Sources and Resources mentioned in the episode:American College of Obstetricians and Gynecologists. Committee Opinion No. 554: Reproductive and Sexual Coercion. American College of Obstetricians and Gynecologists, 2013.American College of Obstetricians and Gynecologists. “Reproductive and Sexual Coercion.” ACOG, Feb. 2013,  https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/02/reproductive-and-sexual-coercion.Centers for Disease Control and Prevention. “About Violence and Pregnancy.” Centers for Disease Control and Prevention,  https://www.cdc.gov/intimate-partner-violence/about/violence-and-pregnancy.html.Centers for Disease Control and Prevention. “Pregnancy Resulting from Sexual Violence.” Centers for Disease Control and Prevention,  https://www.cdc.gov/sexual-violence/about/pregnancy-resulting-from-sexualviolence.html.Cobalt Abortion Fund. Cobalt Abortion Fund,  https://cobaltaf.org/.Colorado Doula Project. Colorado Doula Project,  https://www.coloradodoulaproject.org/.Foster, Diana Greene. The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion. Scribner, 2020.Grace, Kelsey T., and Julie C. Anderson. “Reproductive Coercion: A Systematic Review.” Journal of Midwifery & Women's Health, vol. 63, no. 4, 2018, pp. 371–84.Guttmacher Institute. U.S. Abortion Patient and Policy Reports. Guttmacher Institute, https://www.guttmacher.org.Miller, Elizabeth, et al. “Pregnancy Coercion, Intimate Partner Violence and Unintended Pregnancy.” Contraception, vol. 81, no. 4, 2010, pp. 316–22.National Abortion Federation. National Abortion Federation,  https://prochoice.org/.National Academies of Sciences, Engineering, and Medicine. The Safety and Quality of Abortion Care in the United States. National Academies Press, 2018.“North Carolina Bill Would Authorize Deadly Force for Women Seeking Abortions.” WCNC Charlotte,  https://www.wcnc.com/article/news/politics/north-carolina-politics/north-carolina-bill-would-authorize-deadly-force-for-women-seeking-abortions/275-353d54a3-9231-4341-ae44-a127546db76f.Raymond, Elizabeth G., and David A. Grimes. “The Comparative Safety of Legal Induced Abortion and Childbirth in the United States.” Obstetrics & Gynecology, vol. 119, no. 2, 2012, pp. 215–19.“Reproductive Coercion.” The National Domestic Violence Hotline,  https://www.thehotline.org/resources/reproductive-coercion/.“Reproductive Coercion: What Is It?” Teen Vogue,  https://www.teenvogue.com/story/what-is-reproductive-coercion.Sexual Assault Awareness Fund. “Bisexual Women Are More Likely to Have Abortions.” Sexual Assault Awareness Fund, https://saafund.org/bisexual-women-are-more-likely-to-have-abortions/.Society of Family Planning. #WeCount Reports on Abortion Access After Dobbs. Society of Family Planning,  https://societyfp.org/.Tarzia, Laura, et al. “Reproductive Coercion and Abuse: A Systematic Review of Qualitative Evidence.” Trauma, Violence, & Abuse,  https://pmc.ncbi.nlm.nih.gov/articles/PMC5819992/.Van Parys, An-Sofie, et al. “Prevalence and Evolution of Intimate Partner Violence before and during Pregnancy: A Cross-Sectional Study.” BMC Pregnancy and Childbirth, vol. 14, 2014, article 294,  https://doi.org/10.1186/1471-2393-14-294.Washington State Coalition Against Domestic Violence. Pregnancy and Domestic Violence Issue Brief. Washington State Coalition Against Domestic Violence, 2013,  https://wscadv.org/wp-content/uploads/2016/12/pregnancy-dvfr-issue-brief-12-2013.pdf.World Health Organization. Abortion Care Guideline. World Health Organization, 2022.You can learn more about your options with healthcare service providers like Just the Pill. They can provide vital information and assistance with abortion, contraception, and other sexual and reproductive health services. We provide efficient and equitable access to health care by telemedicine. https://justthepill.com/about-us/You can also look into resources like Elevated Access. They are a nonprofit organization that provides free air transportation through a network of volunteer pilots, helping people travel to essential healthcare services they might not otherwise be able to reach. Their services primarily support access to abortion care and gender-affirming care by coordinating safe, confidential flights in partnership with healthcare and advocacy organizations across the United States.Be aware of Denver Metro Crisis Pregnancy Centers (CPCs):The AVI Project https://www.theaviproject.com/Alternatives Pregnancy Center (Alternatives Colorado) https://youhavealternatives.org/Bella Health and Wellness. Bella Health and Wellness.  https://bellahealthandwellness.com/.Alternatives Pregnancy Center. Alternatives Pregnancy Center.  https://youhavealternatives.org/.Marisol Health. Marisol Health.  https://marisolhealth.com/.Life Choices. Life Choices.  https://lifechoices.org/.If you are in crisis and need immediate support, please call our 24/7 interpersonal violence helpline at 303-556-2255.Request an Appointment with an Advocate athttps://www.thepca.org/online-appointment-requestRequest a Violence Prevention Presentation at https://www.thepca.org/prevention-educationInstagram @phoenixauraria

Postpartum psychosis is a rare but serious mental health emergency that can occur after childbirth, causing symptoms like hallucinations, delusions, paranoia, and severe mood changes. Unlike postpartum depression, postpartum psychosis can involve a loss of touch with reality and requires immediate medical attention. The condition is at the center of the Lindsay Clancy trial, which is now underway. Dan spoke with Dr. Nicole Harrington Cirino, a psychiatrist, member of the Perinatal Psychosis Task Force at Postpartum Support International, and Professor of Psychiatry and Behavioral Sciences and Obstetrics & Gynecology at Baylor College of Medicine, who explained the condition, its symptoms, and how it is diagnosed and treated.See omnystudio.com/listener for privacy information.

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USAFeaturing: Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USARamez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Today, we're diving straight into a topic that hits close to home for millions of patients and providers alike: IUD insertion pain, and more importantly, how we can actually make it better. Now, if you've been practicing or following clinical guidelines for a while, you know the frustrating backstory here. For years, the standard advice was simple: "Just take 800 milligrams of ibuprofen an hour before your appointment." But a 2015 double-blinded, randomized placebo-controlled clinical trial showed that taking a single dose of 800 mg within an hour before insertion did not relieve procedural pain. That was published in the journal Contraception in 2015. This left clinicians wishing for better options. Fast forward to 2024, when the CDC updated its guidelines to formally recommend local analgesia, like lidocaine blocks or topical use, to help manage insertion pain. That was a huge, long-overdue win for patient-centered care. But local numbing isn't the only tool we should be looking at. What if the issue with oral NSAIDs wasn't the medication itself, but how and when we dosed it? That brings us to a brand-new study published in the American Journal of Obstetrics and Gynecology (AJOG), August 2026. Researchers looked at a preemptive, multidose ibuprofen regimen- starting the day before insertion to reach sustained, therapeutic blood levels ahead of time. And the results? They offer some new insights into how we can stack our pain control strategies. So, let's break down what this study found, how it builds on our CDC guidance, and what it means for our clinical practice starting at our next IUD placement. Let's jump in. 1. Bednarek PH, Creinin MD, Reeves MF, et al. Contraception. 2015;91(3):193–197.2. Ouyang C, Lamvu G, Quach H, et al. Multidose Ibuprofen Prior to Intrauterine device insertion (MIPI): a triple blinded randomized controlled trial. American Journal of Obstetrics & Gynecology, August 2026; 235, 330-3373. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No.7 Obstetrics and Gynecology. 2023. Committee on Clinical Practice Guidelines–Gynecology4. McKenna KA, Fogleman CD. Dysmenorrhea.American Family Physician. 2021.

Podcast family, we pride ourselves on this show on being avant-garde and forward thinking on the topics we choose. For example, on February the 20th, 2026, we released an episode called “New Data: Screen Maternal Ferritin with Prenatal Care?” In that episode we reviewed a publication from the previous month (January 2026) that was released in Lancet Hematology. This study made the case for screening for early iron deficiency, even without anemia, with serum ferritin at the initiation of prenatal care. This was a multicenter, 2-arm, randomized controlled trial. Earlier identification of low serum ferritin prevented iron deficiency anemia in the third trimester. That's a win! Back then, we also stated how Australia has been leading the charge on this with the Australian HOW. That stands for Hematology in Obstetrics and Women's Health. This Australian consensus committee now recommends screening for iron deficiency, not just iron deficiency anemia, at the initiation of prenatal care, at 24 to 28 weeks, and then again at the third trimester when necessary. And now, as of August 2026, we have additional supportive data that including serum ferritin at the initial OB visit is evidence-based and best for the patient! In this episode we will review this brand-new, prospective cohort study published as a Research Letter in the AJOG August 2026.1. Australian HOW: Iron optimisation in pregnancy: a Haematology in Obstetric and Women's Health Collaborative consensus statement; https://onlinelibrary.wiley.com/doi/10.1111/imj.166022. Konecke N, Jackson T, Angeles I. et al. The association between first trimester iron deficiency without anemia and the development of iron-deficiency anemia prior to childbirth. American Journal of Obstetrics & Gynecology, 2026; 235, e36-e383. ACOG Clinical Practice Update: An Update to Clinical Guidance for Delayed Umbilical Cord Clamping After Birth in Preterm Neonates. Obstet Gynecol. 2025 Jul 24;146(3):442-444.

Natalie Crawford, MD is double board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and author of the bestselling book, The Fertility Formula. She is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas and CEO and co-founder of Learn at Pinnacle, a medical education network. Dr. Crawford completed her undergraduate at Auburn University obtaining a degree in Nutrition Science, Medical School at University of Texas Medical Branch, OBGYN Residency at University of Texas Southwestern, and REI Fellowship at University of North Carolina, concurrently obtaining a Master of Science in Clinical Research. Today on the show we discuss how cannabis and alcohol affect fertility in men and women, how long reproductive health may take to recover after quitting, the surprising relationship between GLP 1 medications and fertility, how chronic stress and insulin resistance can make it harder to conceive, the five lifestyle habits that support healthier eggs and sperm, and why proactive fertility testing can help couples avoid losing valuable time. Try Momentous Signature Spec Creatine: https://www.livemomentous.com Use code ADVERSITY for up to 35% off your entire first order Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Bleedin' Truth, Dr. Sally McNally sits down to have a conversation with Dr. Jill Hall. Dr. Jill C. Hall is a board-certified Obstetrician/Gynecologist and a fellowship-trained Urogynecologist specializing in Female Pelvic Medicine and Reconstructive Surgery. They cover frequently asked questions including Kegel exercises, stress incontinence, pelvic floor organ prolapse and dysfunction.Dr. Hall received her Bachelor of Science degree in Neuroscience at Brown University. She received her medical degree at the Keck School of Medicine, USC. She completed a residency in obstetrics and gynecology at UCLA and a fellowship in Female Pelvic Medicine and Reconstructive Surgery at Long Beach Memorial Hospital with Dr. Donald Ostergard.Dr. Hall's clinical interests include the evaluation and treatment of urinary and fecal incontinence, pelvic organ prolapse, pelvic pain, and sexual dysfunction. Dr. Hall performs minimally invasive surgeries, including robotic surgeries.Dr. Hall chose to become a Urogynecologist because she believes that being a woman should not have to result in health problems that keep us from living our best lives. She is passionate about educating her patients and treating them with the most up-to-date and evidence-based therapies available. She is a fellow of the American College of Obstetrics and Gynecology and a member of the American Urogynecologic Society."▶ Sally's Childbirth Education & Hypnobirthing Classes: https://drsallymcnally.com/childbirth...▶ Listen to us on Spotify: https://open.spotify.com/show/5awpvBA...▶ Listen to us on Apple Podcasts: https://podcasts.apple.com/us/podcast...

The Bakri Postpartum Balloon was described and first used clinically in 1999 by Dr. Younes N. Bakri (Georgia, USA). It is intended to treat postpartum hemorrhage (PPH). In the United States, it received its first major FDA clearance (via 510(k) for commercial marketing) on April 17, 2002. Manufacturer guidelines for the Bakri (Cook Medical) state that the balloon may be left indwelling for a maximum of 24 hours, but the determination of removal time is left to the clinician once “bleeding is controlled and the patient is stable.” However, the optimal duration of intrauterine balloon tamponade placement remains unclear. One retrospective cohort study from AJOG (Einerson et al) of 274 women found no significant difference in PPH outcomes when intrauterine balloon tamponade was left in place for 2–12 hours, compared with more than 12 hours. However, only 30 women had the intrauterine balloon tamponade placement for 10 hours or less. And remember, this was not a prospective trial looking at a minimum of 2 hours, 2 hours was just the lower margin of the “short duration” group. Now, a new RCT (with authors from Denver and Vermont) published in the July 2026 Green Journal provides new data. In this first of its kind pragmatic, randomized trial of noninferiority, a 6-hour duration of intrauterine balloon tamponade usage for postpartum hemorrhage (PPH) control was compared with an 18-hour duration. Listen in for details. 1. Durfee, J., Adkins, K., Heyborne, K., Larrea, N., & Schultz, C. (2026). Intrauterine Balloon Tamponade Duration for Postpartum Hemorrhage: A Randomized Controlled Trial. Obstetrics & Gynecology, 148(1), 113–120. https://doi.org/10.1097/AOG.00000000000062952. Garabedian C, Prats C, Seco A, Deneux-Tharaux C, Rozenberg P, Berveiller P. Duration of Intrauterine Balloon Tamponade in Post-Partum Haemorrhage Management After Vaginal Delivery: A Secondary Cohort Analysis From the French TUB Trial. BJOG. 2026 Jan;133(1):123-131. doi: 10.1111/1471-0528.18345. Epub 2025 Sep 1. PMID: 40888007; PMCID: PMC12676195.3. Einerson BD, Son M, Schneider P, Fields I, Miller ES. The association between intrauterine balloon tamponade duration and postpartum hemorrhage outcomes. Am J Obstet Gynecol 2017;216:300.e1–5.

INTRODUCING Behind the Knife OBGYN Oral Board Review!The oral boards aren't just about knowledge—they are about executing under pressure. This course is designed to give you the structure and confidence to command the room. We have curated 98 high-yield scenarios covering the "Big Three" of the exam: Obstetrics, Gynecology, and Office Practice. Whether it's a surgical emergency or a complex clinic workup, we will walk you through exactly how to articulate your plan, defend your decisions, and pass this exam.Each scenario includes 2 parts. The first part is a perfectly executed scenario.  If you are able to achieve this level of performance in your preparation you are sure to pass the oral exam with flying colors. The second part introduces high-yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy-to-understand teaching that covers the most confusing topics. We are confident you will find this unique, dual format approach a highly effective way to prepare for the test.Please check out the preview episodes below that include Parts A and B, with and without commentary.This course includes access to our Oral Board Simulator.  Step into the hot seat and experience the pressure of the real exam and receive detailed, actionable feedback with the most advanced oral board prep available.   3-Month Purchase - 10 exams 6-Month Purchase - 22 exams 12-Month Purchase - 46 exams Learn More: https://behindtheknife.org/premium/obgyn-oral-board-reviewDOMINATE THE DAY!

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailOBGYN Dr. Richard Myers joins Dr. Erich Schramm to discuss the name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This syndrome is the combination of three parts: increased polyendocrine hormones (like insulin and androgens), changing metabolism, and differences in ovarian function Dr. Myers explains that the name change to PMOS reflects the changing understanding and focus of the syndrome from a purely ovarian-centered approach to a more holistic, full-body treatment regimen. The doctors also discuss how different patient desires drive different treatment options and the need for individualized, patient-centered care. They finish by looking at new treatments, including GLP-1 and GIP medications that can help address the underlying metabolic components of the PMOS.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

For Dr. Patricia McLelland, becoming a doctor wasn't the plan until a mission trip to Uganda changed everything. In this episode, Tricia shares how being a patient in a third-world hospital shaped the way she practices medicine today, what a mentor taught her about choosing a career based on what she *didn't* enjoy, and how a patient in Portland rewired her entire approach to women's health. Dr. Patricia McLelland is a Specialist in Obstetrics & Gynecology at Galen OB/GYN East. You can read her Substack at https://patriciamclellandmd.substack.com/ or you can connect with her on LinkedIn (https://www.linkedin.com/in/patricia-mclelland-md-3060681b6/).  If you like this episode, we think you'll also like: Dr. Anna George's Morning Cup (E112) Dr. Claudia Kramer's Morning Cup (E115) Dr. Katie Duffy's Morning Cup (E175) Subscribe to the weekly newsletter and be the first to know who upcoming guests are: http://eepurl.com/iGJzII  My Morning Cup is hosted by Mike Costa of Costa Media Advisors and produced by SpeakEasy Productions.

Jill Saberman is a California-based Women's Health Nurse Practitioner. In her professional practices, Jill focuses on Obstetrics & Gynecology, prenatal care, fertility, contraception and menopause. She values helping women understand their bodies, their health, and themselves. In this episode, Jill discusses her philosophy of care which includes these words, “I am forever grateful to be in a partnership with my patients” and focuses on being authentic, being a good listener, and creating a safe space for her patients… professional discretion and compartmentalization… thinking about a career in medicine when she was a child because her father was a physician and her mother is a psychologist and a Biofeedback and Stress Management Practitioner… choosing a different path in college and pursuing art classes and film production classes…graduating with a Bachelor of Arts in Visual Arts with a focus on film, video, and photography… stepping away from the film industry and deciding to consider graduate programs after a conversation with her own OBGYN Nurse Practitioner… pursuing a Masters degree in Nursing Science to become a Women's Health Nurse Practitioner… the winding path that that led her to find her sense of personal empowerment and fulfillment… the importance of sharing our stories and of reminding each other that it is okay to make mistakes while also having a sense of grace for ourselves… and her beautiful closing words, “I would just like for women to be mentors for each other. We all have something that can support, guide, encourage, teach, care, and love for what any individual wants to do or be.”

Think about the last time you had to time something perfectly. Maybe it taking that perfect swing at the baseball, or catching a flight after a commute, or making a high-stakes decision. In the world of high-risk pregnancy, clinicians play a constant game of high-stakes timing with a usual medication called antenatal corticosteroids. Given to moms at risk of giving birth early, these steroids are a gamechanger for a preterm neonate. But there's a catch. If you give them too early, the benefits fade. If you give them too late and she delivers very quickly, they don't have time to work. A brand-new study published in the journal Obstetrics & Gynecology by Mark Clapp et al reveals just how incredibly difficult this balancing act is. This data shows that nearly 26% of pregnant individuals who received these steroids actually went on to deliver completely full-term, exposing babies to medications they might not have needed. So how do we as clinicians solve this OB Goldilocks problem where the stakes are a newborn baby's health? On today's episode, we break down the data behind 'maximizing benefit while avoiding overuse' and what it means for real world practice.Strong Coffee Company - Protein Coffee PLUS MORE; Get 20% OFF | Promo Code: CHAPANOSPINOBG https://promocode.to/strong-coffee-company/chapanospinobg-hbv1. Clapp, Mark A. MD, MPH; Li, Siguo MS; Melamed, Alexander MD, MPH; Reiff, Emily MD; Gyamfi-Bannerman, Cynthia MD, MS; Kaimal, Anjali J. MD, MAS. Maximizing Benefit From Antenatal Steroid Use While Avoiding Overuse. Obstetrics & Gynecology 148(1):p e33-e42, July 20262. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021 Oct;155(1):26-303. Society for Maternal-Fetal Medicine Special Statement: Quality metrics for optimal timing of antenatal corticosteroid administration; 2022

When Ashley Womble decides she wants to start a family, she worries she'll need to stop taking her antidepressant medication. Instead of finding clear guidance, she runs head-first into a troubling reality: many of the questions pregnant women and their physicians face about medication safety remain difficult to answer because pregnant women have historically been excluded from medical research. This episode looks at the ethical trade offs of leaving pregnant women out of medical research—and what happens when they and their doctors must make high stakes healthcare decisions without high quality evidence.This episode features:Ashley Womble, MPH: Writer and marketing professional.Ruth Faden, PhD, MPH: Philip Franklin Wagley Professor of Biomedical Ethics at the Johns Hopkins Berman Institute of Bioethics.Crystal Clark, MD, MSc: Associate Professor, Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto.Marika Toscano, MD, MS: Assistant Professor of Gynecology and Obstetrics at Johns Hopkins University School of Medicine.This episode contains references to suicide, which may be distressing for some listeners. If you or someone you know is struggling, support is available.In the U.S., you can call or text the Suicide and Crisis Lifeline at 988 or the National Maternal Mental Health Hotline at 1-833-TLC-MAMA.For listeners outside the U.S., the International Association for Suicide Prevention can help connect you with support in your area: www.iasp.info/suicidalthoughts/“playing god?” is a podcast by the iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. To read a transcript of this episode, visit the iDeas Lab website at https://bioethics.jhu.edu/pgs2e6.The Johns Hopkins University Sesquicentennial is proud to support this podcast. JHU celebrates 150 years of pioneering education and research—advancing knowledge to meet the challenges of every generation. Learn more at 150.jhu.edu.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490 Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice. Episode resource links: Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995 Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open.  Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology. Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke.  Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke.  Guest: Susan Feeney, DNP, FNP-BC, NP-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Podcast Family, in this episode we will focus on the “20-minute rule” for vacuum assisted vaginal delivery. This is an important aspect of neonatal safety and is a vital part of procedure documentation. Documentation for vacuum assisted vaginal delivery should include station at application, number of tractions, number of pop-offs and the total traction time and the vacuum trackable time (time from first application to delivery). This has historical roots as well as new data to validate it (March 2026). Listen in for details. 1. ACOG PB 219; 20202. Preuss E, Porto A, Sheiman V, Bitton M, Tovbin J, Kedem HI, Barzilay E. When to stop? A single center experience on vacuum-assisted deliveries. Eur J Obstet Gynecol Reprod Biol. 2026 Mar 25;320:114983. 3. Teng FY, Sayre JW. Vacuum Extraction: Does Duration Predict Scalp Injury?.Obstetrics and Gynecology. 1997. 4. Tsakiridis I, Giouleka S, Mamopoulos A, et al.Operative Vaginal Delivery: A Review of Four National Guidelines. Journal of Perinatal Medicine. 2020. 16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG

The March 2026 ACC/AHA Guideline on the Management of Dyslipidemia made a major pivot regarding Lipoprotein(a) by establishing a formal recommendation for universal screening in adults. This 2026 guideline, published in the Journal of the American College of Cardiology, issued a Class 1 recommendation stating that every adult should have their Lp(a) measured at least once in their lifetime. Because Lp(a) levels are genetically determined and remain highly stable throughout a person's life, a single lifetime check is sufficient for the vast majority of the population to establish their baseline risk. Well, that's great for Family medicine or internal medicine, but how does that affect us in women's health? Well, it's complicated: lipoprotein(a) has been associated with an increased risk of VTE and has also been associated, in some studies, with FGR, preeclampsia, and preterm birth! So, can these patients receive oral contraceptives? What about Perioperative and postop care? Do these patients require anticoagulation? What about pregnancy- is LDA recommended here? And lastly, what about TXA use in patients with HMB? This podcast topic comes from one of our podcast family members who is an OBGYN military personnel caring for our wonderful troops overseas. Listen in for details!16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O'Donoghue, M. L., Bikdeli, B., Yu, Z., Natarajan, P., Patel, A. P., Pabon, M. A., & Honigberg, M. C. (2026). Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. European Heart Journal, ehag252. https://doi.org/10.1093/eurheartj/ehag2522.ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Writing Committee. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 153, e1155–e1300. https://doi.org/10.1161/CIR.00000000000014233. CDC MEC 4. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Gynecology5. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D.Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-Analysis of the Literature.Seminars in Thrombosis and Hemostasis. 2017. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein (A) and Venous Thromboembolism in Adults: The American Journal of Medicine. 2007.

Hey everyone, thanks for tuning in. If you've spent any time in the OR during a cesarean delivery, you know that the choice between uterine exteriorization and in situ repair usually comes down to how you were trained or personal surgeon preference. It's a debate as old as modern obstetrics. But a major piece of clarity is coming down the pipeline. This episode, we are getting a sneak peek at a brand-new systematic review and meta-analysis dropping this July 2026 in the European Journal of OBGYN. We're asking the big question: is this the study that finally settles the debate once and for all? Grab your coffee, stick around, and let's find out.16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG​ Coutinho, I. C., Ramos de Amorim, M. M., Katz, L., & Bandeira de Ferraz, Á. A. (2008). Uterine exteriorization compared with in situ repair at cesarean delivery: A randomized controlled trial. Obstetrics & Gynecology, 111(3), 639–647. https://doi.org/10.1097/aog.0b013e31816521e2 . (One of the most heavily cited clinical trials on the subject. It established that women in the exteriorized group experienced a 41% greater risk of moderate-to-severe pain at 6 hours postoperatively compared to the non-exteriorized cohort).​ Tan, H. S., Taylor, R. C., Sharawi, N., Sultana, R., Barton, K. D., & Habib, A. S. (2021). Uterine exteriorization versus in situ repair in Cesarean delivery: A systematic review and meta-analysis. Canadian Journal of Anaesthesia, 69(2), 216–233. https://doi.org/10.1007/s12630-021-02142-8​ Fonseca Queiroz L, Lemos M, Pereira da Silva D . Uterine exteriorization versus in-situ uterine repair during cesarean delivery: a systematic review and meta-analysis of randomized controlled trial. European Journal of Obstetrics and Gynecology and Reproductive Biology, 2026; 323

What happens when a lifelong passion for science, innovation, and helping others comes together in one remarkable career? In this episode of The She Believed She Could™ Podcast, Allison Walsh sits down with Dr. Erica Stockwell, an advanced gynecologic surgeon with AdventHealth for Women, to discuss her groundbreaking work in women's healthcare, minimally invasive surgery, and medical innovation. Dr. Stockwell shares how her background in biomedical engineering, medicine, and business led her to become a pioneer in robotic surgery and surgical technology. From holding medical device patents to helping shape the future of AI-assisted healthcare, she offers a fascinating look at where women's health is headed and why innovation matters more than ever. But beyond her impressive accomplishments, Dr. Stockwell also reveals the deeply personal challenges that shaped her journey. During medical residency, she became a new mother while simultaneously caring for her infant daughter battling cancer. Her powerful story of perseverance, faith, and community support serves as a reminder that even the most successful women face valleys—and that resilience is built by continuing forward through them. Together, Allison and Dr. Stockwell explore leadership, confidence, endometriosis care, women's health advocacy, entrepreneurship, motherhood, and the courage it takes to keep believing in yourself when life gets hard. If you're looking for inspiration, practical wisdom, and a glimpse into the future of healthcare, this conversation is one you won't want to miss. What You'll Learn in This Episode: How innovation is reshaping women's healthcare The benefits of minimally invasive gynecologic surgery Emerging trends in robotic surgery and AI-assisted medicine Why endometriosis requires comprehensive, multidisciplinary care How to build resilience during life's hardest seasons The role of mentorship and support systems in success Why confidence is created through action Lessons on leadership, entrepreneurship, and impact How to navigate motherhood while pursuing ambitious goals The future of women's health technology This episode is sponsored by AdventHealth for Women. Learn more about their Women's Health Navigation Team and how they're making healthcare simpler for women and their families at AdventHealthForWomen.com. Positioned for Partnerships™ Mini Course - Turn your platform into a revenue-generating brand opportunity—without needing a massive following. Learn how to position your brand, create a high-converting media kit, and confidently pitch partnerships so brands instantly understand your value. 

In the ACOG PB 231, Multifetal Gestations Twin Triplet and Higher-Order Multifetal Pregnancies, it states, “based on the improved outcomes reported in singleton gestations, the National Institutes of Health recommends that, unless a contraindication exists, a course of antenatal corticosteroids should be administered to all patients who are at risk of delivery within 7 days and who are between 24 weeks and 34 weeks of gestation, irrespective of the fetal number”. But a BRAND NEW meta-analysis is saying the exact opposite- with a catch. Listen in for details.1. ACOG PB 2312. Felippe, Carolina Alves MS; Ruiz, Sinrraim dos Santos Chaves MD; de Souza, Rebeca Ferreira MS; de Lima, Aliny Silva MS; dos Santos, Priscila Luiza MS; Fonseca, Pandora Eloa Oliveira MS; de Almeida Silva, Ingryd MS; Montes-de-Oca-Saucedo, Carlos Roberto MD; Santana, Ana Cecília Oliveira MS; Veta Darkovski, Jasmina MD; Matlaw, Hadas Rachel MD; Fonseca Queiroz, Laura MD. Antenatal Corticosteroid Use in Twin Pregnancies: A Systematic Review and Meta-analysis. Obstetrics & Gynecology ():10.1097/AOG.0000000000006344, June 4, 2026. | DOI: 10.1097/AOG.000000000000634416% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG

OA1264 - Sherise Doyley was in the early stages of labor, in a hospital bed, preparing to deliver her baby, when nurses wheeled in a computer. On the screen was a judge, notifying her of an emergency order by the State of Florida to attempt to force her to undergo a C-section, instead of first attempting vaginal delivery. For 3 hours she advocated for herself, without an attorney, barely covered in a hospital gown. How was any of this legal? What is happening? Jenessa breaks down the history of our rights to make our own medical decisions and how that is legally modified in pregnancy, Lydia shares her own birth experience and how these situations could be handled with actual compassion, and Thomas holds very still in hopes our eyes are based on movement (just kidding, Thomas is very supportive and also outraged). Come rage against the machine with us and hopefully breathe life into a revived pro-choice movement, before it's too late. Amy Yurkanin (Mar. 14, 2026), They Didn't Want to Have C-Sections. A Judge Would Decide How They Gave Birth, ProPublica. Video clips of Doyley hearing, provided by ProPublica's Facebook page Anuli Njoku, Marian Evans, Lillian Nimo-Sefah, & Jonell Bailey (2023). Listen to the Whispers before They Become Screams: Addressing Black Maternal Morbidity and Mortality in the United States, 11 Healthcare 438. Brad N. Greenwood, Rachel R. Hardeman, Laura Huang, & Aaron Sojourner (2020), Physician–patient racial concordance and disparities in birthing mortality for newborns, 117 Proceedings of the National Academy of Sciences 21194. Maternal Mortality Prevention (Dec. 18, 2025). Data from the Pregnancy Mortality Surveillance System, CDC. Bracey Harris & Elizabeth Chuck (Jan. 9, 2026), 'Her worst fear has come to pass': Midwife who advocated for Black women dies after giving birth, NBC News. Camila Domonoske (Apr. 17, 2018), 'Father Of Gynecology,' Who Experimented On Slaves, No Longer On Pedestal In NYC, NPR. Megan L. Swanson, Sara Whetstone, Tushani Illangasekare, & Amy (Meg) Autry (2021), Obstetrics and Gynecology and Reparations: The Debt We Owe (and Continue to Accumulate), 5 Health Equity 353. Nicole Loy (May 16, 2025), Pain and Gynecology: Raising Standards of Care, The Healthcare Review at Cornell University. Jess Mador (July 29, 2025), A Brain-Dead Pregnant Woman Was Kept Alive in Georgia. It's Unclear if State Law Required It, KFF Health News. (June 2025), Pregnancy Exceptionalism: A Review of Restrictions on Advance Directives, Pregnancy Justice. U.S. Const. amend. IX Jacobson v. Massachusetts, 197 U.S. 11 (1905) Rochin v. California, 342 U.S. 165 (1952) Cruzan v. Director, Missouri Dep't of Health, 497 U.S. 261 (1990) Washington v. Harper, 494 U.S. 210 (1990) Roe v. Wade, 410 U.S. 113 (1973) Planned Parenthood of Southeastern Pa. v. Casey, 505 U.S. 833 (1992) Dobbs v. Jackson Women's Health Organization, 597 U.S. 215 (2022) Heller v. Doe, 509 U.S. 312 (1993) State Dept. of Human Services v. Northern, 563 S.W.2d 197 (1978) Lane v. Candura, 6 Mass. App. Ct. 377 (1978) Koskenoja v. Whitmer, Mich. Ct. Cl. (2026) (Apr. 20, 2026), Michigan Pregnancy Exclusion Law is Unconstitutional, Compassion & Choices. Check out the OA Linktree for all the places to go and things to do!  

When Kemi Doll was in medical school, she learned that Black women are twice as likely to die from uterine cancer as white women, and also suffer disproportionately from other uterine-related conditions. What wasn't explained was why. Now a gynecologic oncologist, Doll has made it her mission to change these trends and improve care for Black women.  She joins Flora to discuss her new book, “A Terrible Strength: The Hidden Crisis of the Black Womb and Your Survival Guide to Healing.” They explore the way systemic racism and the normalization of Black women's pain lead to later diagnoses of uterine cancer and poorer health outcomes for a range of gynecologic conditions including fibroids, endometriosis, and heavy periods. And Doll explains the problem with using reproductive health as a synonym for uterine health.  Guest:  Dr. Kemi Doll is a gynecologic oncologist and professor at the University of Washington Schools of Medicine and Public Health.  Other episodes you may enjoy: Endometriosis Is Common. Why Is Getting Diagnosed So Hard? A Black Physician's Analysis Of The Legacy Of Racism In Medicine Want SciFri gear? Check out our new shop! Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-4-SCIFRI